Roche Holding AG (RHHBY) Stock Analysis & Winston Score

Roche is a Swiss healthcare company that makes prescription medicines and medical diagnostic tools. Its pharmaceutical division sells treatments for cancer, multiple sclerosis, and eye diseases — with drugs like Herceptin, Avastin, and Ocrevus among its best-known products. Its diagnostics division makes the lab equipment and tests that hospitals use to detect diseases, making Roche one of the few companies that both treats and diagnoses illness at scale. Roche earns money by selling branded drugs to hospitals and insurers, and by selling diagnostic instruments and consumables to labs worldwide. It operates globally, with strong revenue from the United States, Europe, and Japan, and generates over $50 billion in annual sales. Its main competitive advantage is its deep pipeline of patented medicines and its integrated diagnostics business, but a key risk is patent expiration — several of its top-selling drugs already face biosimilar competition, which has been pressuring revenue in recent years.